Siglec-15
- 产品详情
- 实验流程
| Primary Accession | Q6ZMC9 |
|---|---|
| Species | Human |
| Sequence | Phe20-Thr263 |
| Purity | > 90% as analyzed by SDS-PAGE |
| Endotoxin Level | < 1 EU/ µg of protein by gel clotting method |
| Biological Activity | Immobilized Anti-Siglec15 at 1.0 µg/ml (100 µl/well) can bind Siglec-15, hFc, Human with a EC50 = 5.184 ng/ml and a linear range of 0.064−200.0 ng/ml when detected by Mouse Anti–Human IgG Fc-HRP. |
| Expression System | HEK 293 |
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS. |
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 µg/ml. |
| Storage & Stability | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Gene ID | 284266 |
|---|---|
| Other Names | Sialic acid-binding Ig-like lectin 15, Siglec-15, CD33 antigen-like 3, SIGLEC15, CD33L3 |
| Target Background | Siglec-15 preferentially recognizes the Neu5Acalpha2-6GalNAcalpha- structure. Siglec-15 associates with the activating adaptor proteins DNAX activation protein (DAP)12 and DAP10 via its lysine residue in the transmembrane domain. Siglec-15 is the second human Siglec identified to have an activating signaling potential; unlike Siglec-14, however, it does not have an inhibitory counterpart. |
For Research Use Only. Not For Use In Diagnostic Procedures.
| Name | SIGLEC15 |
|---|---|
| Synonyms | CD33L3 |
| Function | Binds sialylated glycoproteins. |
| Cellular Location | Membrane; Single-pass type I membrane protein. |
| Tissue Location | Expressed in macrophage and/or dendritic cells of spleen and lymph nodes |
Research Areas
Application Protocols
Provided below are standard protocols that you may find useful for product applications.
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
Cat# PVGS1621
Availability:
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。